Unraveling the epigenetic code of cancer for therapy.
Alterations in the genome and the epigenome are common in most cancers. Changes in epigenetic signatures, including aberrant DNA methylation and histone deacetylation, are among the most prevalent modifications in cancer and lead to dramatic changes in gene expression patterns. Because DNA methylation and histone deacetylation are reversible processes, they have become attractive as targets for cancer epigenetic therapy, both as single agents and as 'enhancing' agents for other treatment strategies. In this review we discuss our current view of the mammalian epigenome, this view has changed over the years because of the availability of novel technologies. We further demonstrate how the profound understanding of epigenetic alterations in cancer will help develop novel strategies for epigenetic therapies.
Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, OH, USA.
Laura T
LT
Smith
Gregory A
GA
Otterson
Christoph
C
Plass
D000970:Antineoplastic Agents / Q000627:therapeutic use; D042002:Chromatin Assembly and Disassembly; D019175:DNA Methylation; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000502:physiology*; D052138:Genes, Neoplasm; D016678:Genome / Q000502:physiology; D006657:Histones / Q000378:metabolism; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009690:Nucleic Acid Conformation
D000970:Antineoplastic Agents; D006657:Histones